VYNE Therapeutics (VYNE) Accumulated Depreciation & Amortization (2018 - 2025)
VYNE Therapeutics (VYNE) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $23000.0 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 475.0% year-over-year to $23000.0, compared with a TTM value of $23000.0 through Dec 2025, up 475.0%, and an annual FY2025 reading of $23000.0, up 475.0% over the prior year.
- Accumulated Depreciation & Amortization was $23000.0 for Q4 2025 at VYNE Therapeutics, up from $12000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $109000.0 in Q4 2021 and bottomed at $4000.0 in Q4 2024.
- Average Accumulated Depreciation & Amortization over 4 years is $37666.7, with a median of $17500.0 recorded in 2025.
- The sharpest move saw Accumulated Depreciation & Amortization plummeted 63.67% in 2021, then skyrocketed 475.0% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $109000.0 in 2021, then crashed by 33.94% to $72000.0 in 2022, then tumbled by 94.44% to $4000.0 in 2024, then surged by 475.0% to $23000.0 in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for VYNE at $23000.0 in Q4 2025, $12000.0 in Q2 2025, and $6000.0 in Q1 2025.